The intrauterine device: How to deploy this strategy in the molecular world? Review

   


Authors: Johannet, P.; Friedman, C. F.
Review Title: The intrauterine device: How to deploy this strategy in the molecular world?
Abstract: Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073. ©2024 American Association for Cancer Research.
Keywords: endometrial neoplasms; pathology; drug therapy; endometrium tumor; fertility preservation; gestagen; levonorgestrel; endometrial hyperplasia; endometrium hyperplasia; procedures; humans; human; female; progestins; intrauterine contraceptive device; intrauterine devices, medicated; intrauterine devices
Journal Title: Clinical Cancer Research
Volume: 30
Issue: 22
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2024-11-15
Start Page: 5001
End Page: 5002
Language: English
DOI: 10.1158/1078-0432.Ccr-24-2034
PUBMED: 39254401
PROVIDER: scopus
PMCID: PMC11567785
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85209828741&doi=10.1158%2f1078-0432.CCR-24-2034&partnerID=40&md5=ee7ddfe4096779a85b2d6e6d5de5b068
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Claire F. Friedman -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Claire Frances Friedman
    118 Friedman
  2. Paul Medalia Johannet
    9 Johannet
Related MSK Work